A 53-year-old woman with primary biliary cholangitis (PBC) has been taking ursodeoxycholic acid for 18 months. Repeat blood tests show: bilirubin 24 μmol/L, ALP 285 U/L (previously 420 U/L at diagnosis), ALT 68 U/L, albumin 38 g/L, INR 1.1, platelets 165 × 10⁹/L. Anti-mitochondrial antibodies remain positive. Which parameter is the best predictor of long-term prognosis and transplant-free survival in PBC?
Q82
A 68-year-old man with a history of ischaemic heart disease is brought to the emergency department with coffee-ground vomiting and melaena for 12 hours. He takes aspirin 75 mg daily and clopidogrel 75 mg daily following coronary stent insertion 8 weeks ago. His pulse is 110 bpm and BP 95/60 mmHg. Hb is 78 g/L. Following initial resuscitation, what is the most appropriate management of his antiplatelet therapy?
Q83
A 44-year-old woman presents with a 3-day history of severe epigastric pain, nausea, and vomiting. She drinks 60 units of alcohol per week. Examination reveals epigastric tenderness and tachycardia. Blood tests show: amylase 1,450 U/L, CRP 180 mg/L, WBC 16.2 × 10⁹/L, calcium 1.95 mmol/L, glucose 12.1 mmol/L, urea 9.8 mmol/L, LDH 520 U/L, AST 180 U/L, PaO₂ 9.8 kPa on room air. According to the modified Glasgow score, what is her predicted severity of acute pancreatitis?
Q84
A 27-year-old man with Crohn's disease affecting the ileum and colon has failed treatment with azathioprine. He is commenced on infliximab. Prior to starting therapy, which screening investigation is most important to perform?
Q85
A 59-year-old man with Child-Pugh C cirrhosis due to alcohol excess is admitted with tense ascites. Diagnostic ascitic tap shows: protein 8 g/L, white cells 150 cells/μL (80% lymphocytes), serum-ascites albumin gradient (SAAG) 18 g/L. Gram stain and culture are negative. What is the most likely cause of his ascites?
Q86
A 36-year-old woman presents with a 9-month history of abdominal bloating, urgency, and alternating bowel habit with no nocturnal symptoms. She opens her bowels 2-4 times daily with loose stools and occasional mucus. She has lost 2 kg in weight. Examination is unremarkable. Blood tests including FBC, CRP, coeliac serology, and thyroid function are normal. Faecal calprotectin is 18 μg/g (normal <50). What is the most appropriate next step in management?
Q87
A 52-year-old man presents with a 4-week history of epigastric pain that is worse at night and relieved by eating. He takes no regular medications and does not smoke. Upper GI endoscopy reveals a 1.5 cm duodenal ulcer. Urease breath test is positive for Helicobacter pylori. What is the most appropriate eradication therapy according to current UK guidelines?
Q88
A 41-year-old woman with ulcerative colitis presents with acute onset right upper quadrant pain, fever of 38.7°C, and jaundice. She has had colitis for 8 years with intermittent flares. Blood tests show: bilirubin 78 μmol/L, ALT 145 U/L, ALP 520 U/L, GGT 380 U/L. MRCP demonstrates multifocal strictures and beading of both intrahepatic and extrahepatic bile ducts with no evidence of choledocholithiasis. What is the most important long-term complication associated with this condition?
Q89
A 64-year-old man with known cirrhosis secondary to hepatitis B presents to the emergency department with confusion and asterixis. His wife reports he has become increasingly drowsy over the past 48 hours. Blood tests show: albumin 28 g/L, bilirubin 65 μmol/L, INR 2.1, sodium 132 mmol/L, potassium 3.2 mmol/L, urea 8.2 mmol/L, creatinine 95 μmol/L. He is not taking any regular medications. What is the most appropriate initial management?
Q90
A 51-year-old woman with Child-Pugh B cirrhosis due to non-alcoholic steatohepatitis undergoes surveillance ultrasound which identifies a 2.8 cm liver lesion. Multiphase CT shows arterial hyperenhancement with washout in the portal venous phase. AFP is 45 ng/mL. She has no extrahepatic disease. ECOG performance status is 0. According to Barcelona Clinic Liver Cancer (BCLC) staging, what is the most appropriate treatment?
Gastroenterology & Hepatology UK Medical PG Practice Questions and MCQs
Question 81: A 53-year-old woman with primary biliary cholangitis (PBC) has been taking ursodeoxycholic acid for 18 months. Repeat blood tests show: bilirubin 24 μmol/L, ALP 285 U/L (previously 420 U/L at diagnosis), ALT 68 U/L, albumin 38 g/L, INR 1.1, platelets 165 × 10⁹/L. Anti-mitochondrial antibodies remain positive. Which parameter is the best predictor of long-term prognosis and transplant-free survival in PBC?
A. Improvement in serum albumin levels
B. Reduction in alkaline phosphatase to <1.67 times upper limit of normal (Correct Answer)
C. Normalization of serum bilirubin
D. Persistent positive anti-mitochondrial antibodies
E. Decline in platelet count indicating portal hypertension
Explanation: ***Reduction in alkaline phosphatase to <1.67 times upper limit of normal***
- In **Primary Biliary Cholangitis (PBC)**, the biochemical response to **Ursodeoxycholic acid (UDCA)** after 12-24 months is the strongest predictor of **transplant-free survival**.
- Specifically, achieving a reduction in **Alkaline Phosphatase (ALP)** to levels below **1.67 times the upper limit of normal** (as per the Toronto or Globe criteria) is associated with a significantly better long-term prognosis.
*Improvement in serum albumin levels*
- While **albumin** reflects synthetic liver function, its improvement is less specific as a prognostic marker compared to the **biochemical response** of cholestatic enzymes.
- Albumin levels typically stay within the reference range until the disease reaches **advanced cirrhosis**.
*Normalization of serum bilirubin*
- Elevated **bilirubin** is an indicator of **advanced disease** or late-stage PBC and is used as a terminal prognostic marker rather than a measure of early treatment response.
- Although bilirubin remains a component of the **Paris-I criteria**, ALP reduction is recognized as the more sensitive early surrogate for long-term clinical outcome.
*Persistent positive anti-mitochondrial antibodies*
- **Anti-mitochondrial antibodies (AMA)** are diagnostic for PBC but their **titer or persistence** does not correlate with disease severity, progression, or response to therapy.
- Changes in AMA status have no clinical utility in predicting **transplant-free survival** or treatment efficacy.
*Decline in platelet count indicating portal hypertension*
- A declining **platelet count** is a surrogate marker for **portal hypertension** and splenic sequestration, indicative of progressing fibrosis.
- While it highlights disease progression, it is not the primary parameter used to define the **biochemical response** to UDCA that guides early treatment modifications.
Question 82: A 68-year-old man with a history of ischaemic heart disease is brought to the emergency department with coffee-ground vomiting and melaena for 12 hours. He takes aspirin 75 mg daily and clopidogrel 75 mg daily following coronary stent insertion 8 weeks ago. His pulse is 110 bpm and BP 95/60 mmHg. Hb is 78 g/L. Following initial resuscitation, what is the most appropriate management of his antiplatelet therapy?
A. Stop both aspirin and clopidogrel immediately
B. Continue both aspirin and clopidogrel (Correct Answer)
C. Stop clopidogrel but continue aspirin
D. Replace both agents with a single antiplatelet agent such as prasugrel
E. Stop aspirin but continue clopidogrel
Explanation: ***Continue both aspirin and clopidogrel***- In patients with a **coronary stent** inserted within the last 3-6 months, the risk of **stent thrombosis** (mortality 20-45%) often outweighs the risk of gastrointestinal bleeding.- Guidelines generally recommend maintaining **dual antiplatelet therapy (DAPT)** while managing the bleed with **urgent endoscopy**, haemostatic techniques, and high-dose **PPI therapy**.*Stop both aspirin and clopidogrel immediately*- Stopping both agents in a patient only 8 weeks post-stent insertion significantly increases the risk of **major adverse cardiovascular events** and sudden death.- Complete cessation is only reserved for **uncontrolled, life-threatening haemorrhage** that cannot be managed by endoscopic means.*Stop clopidogrel but continue aspirin*- While continuing **aspirin monotherapy** is standard for some secondary prevention patients with GI bleeds, it is insufficient to prevent thrombosis in the **early post-stent period**.- Clopidogrel is specifically required alongside aspirin as part of **DAPT** to ensure the patency of the newly endothelializing stent.*Replace both agents with a single antiplatelet agent such as prasugrel*- **Prasugrel** is a more potent antiplatelet agent than clopidogrel and would likely **increase the risk of bleeding** rather than mitigate it.- Switching agents does not address the acute bleeding episode and deviates from established **DAPT protocols** for post-PCI patients.*Stop aspirin but continue clopidogrel*- There is no clinical evidence to support stopping **aspirin** while continuing clopidogrel to manage a GI bleed in the context of recent stenting.- **Aspirin** is the cornerstone of antiplatelet therapy, and maintaining the synergy of both drugs is vital for **stent protection** during the first 3 months.
Question 83: A 44-year-old woman presents with a 3-day history of severe epigastric pain, nausea, and vomiting. She drinks 60 units of alcohol per week. Examination reveals epigastric tenderness and tachycardia. Blood tests show: amylase 1,450 U/L, CRP 180 mg/L, WBC 16.2 × 10⁹/L, calcium 1.95 mmol/L, glucose 12.1 mmol/L, urea 9.8 mmol/L, LDH 520 U/L, AST 180 U/L, PaO₂ 9.8 kPa on room air. According to the modified Glasgow score, what is her predicted severity of acute pancreatitis?
A. Mild pancreatitis (score 0-2)
B. Severe pancreatitis (score ≥3) (Correct Answer)
C. Moderately severe pancreatitis (score 2)
D. Cannot be assessed as scoring requires 48-hour parameters
E. Indeterminate as abdominal imaging is required for severity assessment
Explanation: ***Severe pancreatitis (score ≥3)***
- The patient scores **3 points** based on **WBC >15 × 10⁹/L** (16.2), **Glucose >10 mmol/L** (12.1), and **Calcium <2 mmol/L** (1.95), directly meeting the threshold for severe pancreatitis.
- A **modified Glasgow score** of 3 or more indicates severe acute pancreatitis, which carries a higher risk of **organ failure** and **mortality**, often requiring intensive care.
*Mild pancreatitis (score 0-2)*
- Mild acute pancreatitis is indicated by a **Glasgow score of 0, 1, or 2**, which is lower than this patient's calculated score of 3.
- Patients with mild pancreatitis typically have no **organ failure** and resolve without significant complications.
*Moderately severe pancreatitis (score 2)*
- This patient's score of 3 exceeds the value for **moderately severe pancreatitis** (often defined by transient organ failure in the **Atlanta classification**, not directly by a Glasgow score of 2).
- A score of 2 would imply fewer severe prognostic indicators than those present in this patient, who has **leukocytosis**, **hyperglycemia**, and **hypocalcemia**.
*Cannot be assessed as scoring requires 48-hour parameters*
- While the **Glasgow score** can be re-evaluated at 48 hours to assess evolving severity, initial scoring is crucial for **early risk stratification** at admission.
- All the necessary **biochemical and physiological parameters** required for an initial assessment were provided in the patient's presentation.
*Indeterminate as abdominal imaging is required for severity assessment*
- The **modified Glasgow score** is a clinical and biochemical prediction tool for severity and does not require **abdominal imaging** like CT or MRI for its calculation.
- Imaging is primarily used to identify **local complications** such as necrosis or fluid collections, rather than for the initial prognostic scoring.
Question 84: A 27-year-old man with Crohn's disease affecting the ileum and colon has failed treatment with azathioprine. He is commenced on infliximab. Prior to starting therapy, which screening investigation is most important to perform?
A. Cytomegalovirus IgG and IgM
B. Varicella zoster IgG antibodies
C. Hepatitis B surface antigen and core antibodies
D. Quantiferon-TB Gold test or tuberculin skin test (Correct Answer)
E. HIV antibody testing
Explanation: ***Quantiferon-TB Gold test or tuberculin skin test***
- **Anti-TNF** therapy, such as **infliximab**, significantly increases the risk of **latent tuberculosis reactivation** into disseminated or extrapulmonary disease.
- Mandatory screening via **Interferon-Gamma Release Assays (IGRAs)** or skin testing, often combined with a **chest X-ray**, must be performed prior to treatment initiation.
*Cytomegalovirus IgG and IgM*
- While **CMV reactivation** can occur in immunocompromised patients, it is not a routine mandatory screening requirement before starting **TNF inhibitors**.
- CMV testing is more commonly reserved for patients with **steroid-refractory ulcerative colitis** to rule out opportunistic infection of the colon.
*Varicella zoster IgG antibodies*
- Assessment of **Varicella immunity** is recommended to determine the risk of serious primary infection, but it is not the most critical screening compared to TB.
- Patients found to be seronegative may require **vaccination** with a live-attenuated vaccine before starting immunosuppression, if time allows.
*Hepatitis B surface antigen and core antibodies*
- Screening for **Hepatitis B (HBV)** is important because **anti-TNF** agents can trigger **viral reactivation** and potentially fatal hepatic flare.
- Although important, TB screening is prioritized in clinical guidelines due to the high mortality and public health implications of **tuberculosis flare-ups**.
*HIV antibody testing*
- While knowing a patient's **HIV status** is clinically useful when managing chronic immunosuppression, it is not a mandatory prerequisite for **infliximab** therapy.
- HIV remains a consideration for overall patient safety but does not carry the same specific reactivation risk profile as **latent tuberculosis** under TNF blockade.
Question 85: A 59-year-old man with Child-Pugh C cirrhosis due to alcohol excess is admitted with tense ascites. Diagnostic ascitic tap shows: protein 8 g/L, white cells 150 cells/μL (80% lymphocytes), serum-ascites albumin gradient (SAAG) 18 g/L. Gram stain and culture are negative. What is the most likely cause of his ascites?
A. Spontaneous bacterial peritonitis
B. Portal hypertension secondary to cirrhosis (Correct Answer)
C. Peritoneal carcinomatosis
D. Tuberculous peritonitis
E. Nephrotic syndrome
Explanation: ***Portal hypertension secondary to cirrhosis***
- A **Serum-Ascites Albumin Gradient (SAAG) ≥ 11 g/L** (18 g/L in this case) is highly indicative of **portal hypertension**, which is a direct consequence of the patient's severe liver cirrhosis.
- The ascitic fluid protein of **8 g/L is low (< 25 g/L)**, consistent with a **transudative** fluid accumulation characteristic of uncomplicated ascites due to portal hypertension.
*Spontaneous bacterial peritonitis*
- This diagnosis requires an **ascitic neutrophil count ≥ 250 cells/μL**. The patient's total white cell count is only 150 cells/μL, making SBP highly unlikely.
- While it's a complication of cirrhosis, the primary cause of the ascites as per the tap results is not an acute infection given the cell count.
*Peritoneal carcinomatosis*
- This condition typically presents with a **low SAAG (< 11 g/L)**, as it's an exudative process rather than a hydrostatic one.
- Ascitic fluid in malignancy usually shows **high protein levels (> 25 g/L)**, contrary to the 8 g/L found here.
*Tuberculous peritonitis*
- Although often associated with **lymphocytic predominance**, it is an exudative process, leading to a **low SAAG (< 11 g/L)**.
- It would also typically show a much higher **ascitic protein concentration** (often > 25 g/L or 30 g/L) than observed in this patient.
*Nephrotic syndrome*
- Ascites in nephrotic syndrome is caused by **hypoalbuminemia** leading to a **low SAAG (< 11 g/L)** due to reduced oncotic pressure.
- The patient's **high SAAG (18 g/L)** definitively rules out nephrotic syndrome as the cause of ascites.
Question 86: A 36-year-old woman presents with a 9-month history of abdominal bloating, urgency, and alternating bowel habit with no nocturnal symptoms. She opens her bowels 2-4 times daily with loose stools and occasional mucus. She has lost 2 kg in weight. Examination is unremarkable. Blood tests including FBC, CRP, coeliac serology, and thyroid function are normal. Faecal calprotectin is 18 μg/g (normal <50). What is the most appropriate next step in management?
A. Reassure and commence empirical mebeverine and loperamide
B. Arrange colonoscopy to exclude inflammatory bowel disease (Correct Answer)
C. Trial of a low FODMAP diet with dietitian support
D. Arrange CT abdomen and pelvis to investigate weight loss
E. Commence empirical rifaximin for suspected small intestinal bacterial overgrowth
Explanation: ***Arrange colonoscopy to exclude inflammatory bowel disease***
- In a patient presenting with **unexplained weight loss** and altered bowel habits, a **colonoscopy** is mandatory to exclude organic pathology such as **colorectal malignancy** or **inflammatory bowel disease (IBD)**.
- While a normal **faecal calprotectin** (<50 μg/g) makes IBD less likely, it is not 100% sensitive and does not rule out other structural abnormalities in the presence of **red flag symptoms** like weight loss.
*Reassure and commence empirical mebeverine and loperamide*
- Empirical treatment for **Irritable Bowel Syndrome (IBS)** is inappropriate before excluding organic disease, especially when **red flag features** like weight loss are present.
- Mebeverine (an antispasmodic) and loperamide (an antidiarrheal) treat symptoms but would delay the diagnosis of potentially serious underlying conditions.
*Trial of a low FODMAP diet with dietitian support*
- A **low FODMAP diet** is an effective second-line management strategy for **IBS**, but a positive diagnosis of IBS can only be safely made after excluding organic causes.
- Relying on dietary changes while the patient is losing weight may lead to further **nutritional deficiencies** and missed pathology.
*Arrange CT abdomen and pelvis to investigate weight loss*
- While CT can investigate weight loss and gross structural changes, it is not the primary modality for evaluating the **colonic mucosa** for conditions like IBD or early-stage malignancy.
- A **colonoscopy** allows for direct visualization and **biopsy**, making it the diagnostic gold standard for the lower gastrointestinal symptoms described.
*Commence empirical rifaximin for suspected small intestinal bacterial overgrowth*
- **Small intestinal bacterial overgrowth (SIBO)** can present with bloating and diarrhea; however, **rifaximin** should not be used empirically without diagnostic testing like a hydrogen breath test.
- More importantly, SIBO does not typically explain significant **weight loss**, which must be prioritized through more definitive investigations like endoscopy.
Question 87: A 52-year-old man presents with a 4-week history of epigastric pain that is worse at night and relieved by eating. He takes no regular medications and does not smoke. Upper GI endoscopy reveals a 1.5 cm duodenal ulcer. Urease breath test is positive for Helicobacter pylori. What is the most appropriate eradication therapy according to current UK guidelines?
A. Omeprazole, amoxicillin, and clarithromycin for 7 days
B. Omeprazole, metronidazole, clarithromycin, and bismuth for 14 days
C. Omeprazole, amoxicillin, clarithromycin, and metronidazole for 14 days (Correct Answer)
D. Omeprazole, amoxicillin, and metronidazole for 7 days
E. Omeprazole and amoxicillin for 14 days
Explanation: ***Omeprazole, amoxicillin, clarithromycin, and metronidazole for 14 days***
- Current **NICE guidelines** and the **British Society of Gastroenterology** recommend **concomitant quadruple therapy** (PPI + three antibiotics) for 14 days as a first-line treatment for *H. pylori* eradication.
- This regimen is preferred due to rising **antibiotic resistance** (especially to clarithromycin), providing superior eradication rates exceeding 90%.
*Omeprazole, amoxicillin, and clarithromycin for 7 days*
- This was the traditional **triple therapy**; however, it is no longer the preferred first-line choice in the UK due to its declining efficacy against resistant strains.
- A **7-day duration** is now considered less effective than the standard **14-day duration** for achieving complete eradication.
*Omeprazole, metronidazole, clarithromycin, and bismuth for 14 days*
- This is **bismuth-containing quadruple therapy**, which is typically reserved as a **second-line treatment** or for patients with a **penicillin allergy**.
- Since this patient has no documented penicillin allergy, **amoxicillin-based** quadruple therapy is the standard first-line approach.
*Omeprazole, amoxicillin, and metronidazole for 7 days*
- This is an alternative triple therapy regimen with a short duration that does not meet the current **quadruple therapy** standards for first-line treatment.
- **Triple therapy** is generally avoided as the initial empiric choice unless local resistance patterns specifically favor it or quadruple therapy is contraindicated.
*Omeprazole and amoxicillin for 14 days*
- **Dual therapy** is insufficient for *H. pylori* eradication and is not a recommended standard of care in clinical guidelines.
- Effective eradication requires the synergistic effect of at least **two or three antibiotics** combined with acid suppression.
Question 88: A 41-year-old woman with ulcerative colitis presents with acute onset right upper quadrant pain, fever of 38.7°C, and jaundice. She has had colitis for 8 years with intermittent flares. Blood tests show: bilirubin 78 μmol/L, ALT 145 U/L, ALP 520 U/L, GGT 380 U/L. MRCP demonstrates multifocal strictures and beading of both intrahepatic and extrahepatic bile ducts with no evidence of choledocholithiasis. What is the most important long-term complication associated with this condition?
A. Hepatocellular carcinoma
B. Cholangiocarcinoma (Correct Answer)
C. Secondary biliary cirrhosis
D. Portal vein thrombosis
E. Autoimmune hepatitis overlap syndrome
Explanation: ***Cholangiocarcinoma***
- The patient's presentation with a history of **ulcerative colitis**, cholestatic liver enzymes, and **MRCP findings of multifocal strictures and beading of bile ducts** is pathognomonic for **Primary Sclerosing Cholangitis (PSC)**.
- **Cholangiocarcinoma** is the most significant and feared long-term malignant complication of PSC, occurring in approximately 10-15% of patients, and surveillance for this is crucial.
*Hepatocellular carcinoma*
- While **cirrhosis**, which can result from advanced PSC, is a risk factor for **hepatocellular carcinoma (HCC)**, HCC is significantly less common in PSC compared to **cholangiocarcinoma**.
- HCC is more typically associated with chronic viral hepatitis (B or C) or alcoholic liver disease, rather than the primary biliary pathology of PSC.
*Secondary biliary cirrhosis*
- **Secondary biliary cirrhosis** describes the irreversible liver damage and **fibrosis** that develops over time due to chronic bile duct obstruction and inflammation in PSC.
- It represents the *progression* of the disease to end-stage liver failure rather than a distinct, specific complication like a malignancy, which is what the question implies by "most important long-term complication."
*Portal vein thrombosis*
- **Portal vein thrombosis** can occur as a complication of **cirrhosis** and **portal hypertension**, which can develop in advanced PSC.
- However, it is a non-specific complication of end-stage liver disease and not the *most important* long-term complication directly and uniquely associated with the pathophysiology of PSC, unlike cholangiocarcinoma.
*Autoimmune hepatitis overlap syndrome*
- **Autoimmune hepatitis (AIH) overlap syndrome** with PSC is a recognized variant where patients exhibit features of both conditions, particularly common in younger individuals.
- This is considered a **co-existing condition** or a specific presentation variant of PSC rather than a long-term complication that *develops from* established PSC.
Question 89: A 64-year-old man with known cirrhosis secondary to hepatitis B presents to the emergency department with confusion and asterixis. His wife reports he has become increasingly drowsy over the past 48 hours. Blood tests show: albumin 28 g/L, bilirubin 65 μmol/L, INR 2.1, sodium 132 mmol/L, potassium 3.2 mmol/L, urea 8.2 mmol/L, creatinine 95 μmol/L. He is not taking any regular medications. What is the most appropriate initial management?
A. Intravenous antibiotics and lactulose (Correct Answer)
B. Branched-chain amino acid supplementation
C. Protein restriction to <40g per day
D. High-dose thiamine and IV dextrose
E. Urgent liver transplant assessment
Explanation: ***Intravenous antibiotics and lactulose***
- The patient's confusion and asterixis in the setting of cirrhosis strongly suggest **hepatic encephalopathy (HE)**. **Lactulose** is the first-line treatment, reducing ammonia production and absorption by acidifying the gut lumen and promoting laxation.
- **Infection**, such as **spontaneous bacterial peritonitis (SBP)**, is a common precipitant of HE in cirrhotic patients. Therefore, **empirical intravenous antibiotics** are crucial alongside lactulose to address potential underlying infection.
*Branched-chain amino acid supplementation*
- While **branched-chain amino acids (BCAAs)** can be considered for chronic or refractory hepatic encephalopathy, they are not the primary initial treatment for acute decompensation.
- BCAAs do not address the immediate precipitants of acute encephalopathy, such as infection or gastrointestinal bleeding, as effectively as lactulose and antibiotics.
*Protein restriction to <40g per day*
- **Severe protein restriction** is an outdated practice that can lead to **malnutrition** and sarcopenia, worsening outcomes in cirrhotic patients.
- Current recommendations advise adequate protein intake (1.2–1.5 g/kg/day) to maintain muscle mass, which plays a role in ammonia detoxification.
*High-dose thiamine and IV dextrose*
- This treatment is specific for **Wernicke's encephalopathy**, typically seen in **alcohol-related liver disease** due to thiamine deficiency, which is not the primary etiology in this hepatitis B patient.
- While general supportive care, this regimen does not directly address the pathophysiology of ammonia accumulation or potential infection in acute hepatic encephalopathy.
*Urgent liver transplant assessment*
- Although the patient has decompensated cirrhosis, the immediate priority is to **stabilize the acute episode** of hepatic encephalopathy by treating its underlying precipitants.
- **Urgent liver transplant assessment** is a long-term management strategy, usually pursued after acute medical issues are controlled and the patient is stable for evaluation.
Question 90: A 51-year-old woman with Child-Pugh B cirrhosis due to non-alcoholic steatohepatitis undergoes surveillance ultrasound which identifies a 2.8 cm liver lesion. Multiphase CT shows arterial hyperenhancement with washout in the portal venous phase. AFP is 45 ng/mL. She has no extrahepatic disease. ECOG performance status is 0. According to Barcelona Clinic Liver Cancer (BCLC) staging, what is the most appropriate treatment?
A. Liver transplantation assessment (Correct Answer)
B. Transarterial chemoembolisation (TACE)
C. Sorafenib therapy
D. Surgical resection
E. Radiofrequency ablation
Explanation: ***Liver transplantation assessment***
- The patient's **Hepatocellular Carcinoma (HCC)** meets the **Milan criteria** (single lesion ≤5 cm) and she has **Child-Pugh B cirrhosis**, making liver transplantation the preferred curative treatment.
- This approach is optimal as it simultaneously treats the **malignancy** and the underlying **decompensated liver disease**, offering superior long-term survival compared to other options.
*Transarterial chemoembolisation (TACE)*
- TACE is primarily indicated for **BCLC Stage B (intermediate stage)** HCC, typically involving multinodular disease without vascular invasion or extrahepatic spread.
- It is a palliative locoregional therapy and not the first-line curative option for a patient who is a candidate for liver transplantation.
*Sorafenib therapy*
- This systemic therapy is reserved for **BCLC Stage C (advanced stage)** HCC, characterized by **macrovascular invasion** or **extrahepatic metastases**.
- The patient has localized disease without these advanced features, rendering sorafenib inappropriate as a primary treatment.
*Surgical resection*
- Surgical resection is generally contraindicated in patients with **Child-Pugh B or C cirrhosis** due to the significantly high risk of **postoperative liver failure**.
- It is typically reserved for patients with **preserved liver function** (Child-Pugh A) and solitary tumors (**BCLC Stage 0 or A**).
*Radiofrequency ablation*
- RFA is a curative-intent local ablative therapy often used for **very early/early stage HCC** (lesions ≤3 cm), especially when surgery is not feasible.
- While an option, in the setting of **Child-Pugh B cirrhosis** and a tumor within Milan criteria, liver transplantation offers the best long-term outcomes by treating both the tumor and the underlying liver disease.
